[1] Marin D, Li Y, Basar R, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial[J].Nat Med, 2024, 30:772-784.doi: 10.1038/s41591-023-02785-8. [2] Toffoli EC, van Vliet AA, Forbes C, et al. Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer associated conditions[J]. Clin Exp Immunol, 2024, 216:159-171.doi: 10.1093/cei/uxae007. [3] Sarvaria A, Jawdat D, Madrigal JA, et al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications[J]. Front Immunol, 2017, 8:329. doi: 10.3389/fimmu.2017.00329 [4] Zhang BB, Yang MZ, Zhang WM, et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside[J]. Cell Death Dis, 2024,15:50. doi: 10.1038/s41419-024-06438-7. [5] Berjis A, Muthumani D, Aguilar OA, et al. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation[J].Nat Commun, 2024, 15:3937.doi: 10.1038/s41467-024-47574-0. [6] Almutairi A, Alshehri NA, Subayyil A, et al.Human decidua basalis mesenchymal stem/stromal cells enhance anticancer properties of human natural killer cells, in vitro[J].Front Cell Dev Biol, 2024, 12:1435484.doi: 10.3389/fcell.2024.1435484. [7] Wang JS, Metheny L. Umbilical cord blood derived cellular therapy: advances in clinical development[J]. Front Oncol, 2023, 3:1167266. doi: 10.3389/fonc.2023.1167266. [8] Gao HB, Liu M, Zhang YW, et al. Multifaceted characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and placental blood[J]. Cancer Cell Int, 2022, 22:291. doi: 10.1186/s12935-022-02697-6. [9] Wu YL, Wang Y, Ji J, et al.A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantation[J]. Ann Hematol, 2023, 102:3229-3237. doi: 10.1007/s00277-023-05471-4. [10] Kang L, Voskinarian-Berse V, Law E, et al. Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy[J]. Front Immunol, 2013, 4:101. doi: 110.3389/fimmu.2013.00101. [11] Roudsari PP,Alavi-Moghadam S,Aghayan HR, et al. GMP-based isolation of full-term human placenta-derived NK cells for CAR-NK cell therapy in malignant melanoma[J].Methods Mol Biol, 2024, 2849:203-213.doi: 10.1007/7651_2023_503. [12] Xie BG, Zhang LS, Gao JH, et al. Decoding the biological properties and transcriptomic landscapes of human natural killer cells derived from bone marrow and umbilical cord blood[J]. Am J Cancer Res,2023, 13:2087-2103. [13] Oberoi P, Kamenjarin K, Ossa JFV, et al.Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity[J].Cells, 2020, 9:811. doi: 10.3390/cells9040811. [14] Ghaedrahmati F, Esmaeil N, Akbari V, et al. More balance toward activating receptors and cytotoxic activity of NK cells ex vivo differentiated from human umbilical cord blood-derived CD34+ stem cells in comparison with peripheral blood NK cells[J].Heliyon,2024, 10:e35509. doi: 10.1016/j.heliyon.2024.e35509. [15] Hooijmaijers L,Vidal-Manrique M, SpilsGood B, et al. Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2R g null mice[J].Cell Mol Life Sci,2025, 82:210.doi: 10.1007/s00018-025-05727-4. [16] Kunkanjanawan H, Somredngan S, Kunkanjanawan T, et al.Efficient large-scale expansion of cord blood-derived NK cells: leveraging lipopolysaccharide for enhanced NK cell production[J].Cytotherapy, 2025, 27:782-789.doi: 10.1016/j.jcyt.2025.02.006. [17] Guo X, Mahlakõiv T, Ye Q, et al.CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy[J].J Immunother Cancer, 2021, 9:e001975.doi: 10.1136/jitc-2020-001975. [18] Hegewisch-Solloa E, Nalin AP, Freud AG, et al.Deciphering the localization and trajectory of human natural killer cell development[J].J Leukoc Biol, 2023, 114:487-506.doi: 10.1093/jleuko/qiad027. [19] Niu ZY,Wang MJ, Yan YC, et al. Challenges in the development of NK-92 cells as an effective universal Off-the-Shelf cellular therapeutic[J].J Immunol, 2024,213:1318-1328.doi: 10.4049/jimmunol.2400173. [20] Yin XF, Zhang ZH, Qiu JX, et al. METTL3 positively regulates the development and cytotoxicity of human embryonic stem cells-derived NK cells[J]. Cell Immunol, 2025:415-416.doi: 10.1016/j.cellimm.2025.105011. [21] Zhang L, Weiskittel TM, Zhu YQ, et al. Comparative dissection of transcriptional landscapes of human iPSC-NK differentiation and NK cell development[J]. Life Med, 2024, 3:lnae032.doi: 10.1093/lifemedi/lnae032. [22] Lei W, Liu H, Deng WH, et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial[J].Nat Cancer, 2025, 6:786-800.doi: 10.1038/s43018-025-00940-3. [23] Delehedde C, Ciganek I, Bernard PL, et al. Enhancing natural killer cells proliferation and cytotoxicity using imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA[J].Mol Ther Nucleic Acids, 2024, 35:02263.doi: 10.1016/j.omtn.2024.102263. [24] Golubovskaya V, Sienkiewicz J, Sun JY, et al. CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo[J].Int J Mol Sci,v2023, v24:13364.doi: 10.3390/ijms241713364. [25] Wu SQ, Shi L, Su KX, et al.Carbonate-bearing ionizable lipids for mRNA delivery to splenic NK cells[J].J Am Chem Soc, 2025, 147: 28665-28673.doi: 10.1021/jacs.5c01389. |